Diabetes and COVID-19 testing, positivity, and mortality : A population-wide study in Northern Italy
Copyright © 2022 Elsevier B.V. All rights reserved..
AIMS: To assess if patients with type 2 diabetes mellitus (DM2) are: a) at excess risk of undergoing testing, contracting, and dying from SARS-CoV-2 infection compared to the general population; b) whether cardiovascular diseases (CAVDs) contribute to COVID-19-related death; and c) what is the effect of DM2 duration and control on COVID-19-related death.
METHODS: This population-based study involved all 449,440 adult residents of the Reggio Emilia province, Italy. DM2 patients were divided in groups by COVID testing, presence of CAVDs and COVID death. Several mediation analyses were performed.
RESULTS: Patients with DM2 had an increased likelihood of being tested (Odds ratio, OR 1.27 95 %CI 1.23-1.30), testing positive (OR 1.21 95 %CI 1.16-1.26) and dying from COVID-19 (OR 1.75 95 %CI 1.54-2.00). COVID-19-related death was almost three times higher among obese vs non-obese patients with DM2 (OR 4.3 vs 1.6, respectively). For COVID-19 death, CAVDs mediated a) just 5.1 % of the total effect of DM2, b) 40 % of the effect of DM2 duration, and c) did not mediate the effect of glycemic control.
CONCLUSIONS: For COVID-19-related deaths in DM2 patients, the effect is mostly direct, obesity amplifies it, DM2 control and duration are important predictors, while CAVDs only slightly mediates it.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:191 |
|---|---|
| Enthalten in: |
Diabetes research and clinical practice - 191(2022) vom: 10. Sept., Seite 110051 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Djuric, Olivera [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 05.10.2022 Date Revised 17.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.diabres.2022.110051 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345483391 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345483391 | ||
| 003 | DE-627 | ||
| 005 | 20231226025146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diabres.2022.110051 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345483391 | ||
| 035 | |a (NLM)36030900 | ||
| 035 | |a (PII)S0168-8227(22)00865-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Djuric, Olivera |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diabetes and COVID-19 testing, positivity, and mortality |b A population-wide study in Northern Italy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2022 | ||
| 500 | |a Date Revised 17.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a AIMS: To assess if patients with type 2 diabetes mellitus (DM2) are: a) at excess risk of undergoing testing, contracting, and dying from SARS-CoV-2 infection compared to the general population; b) whether cardiovascular diseases (CAVDs) contribute to COVID-19-related death; and c) what is the effect of DM2 duration and control on COVID-19-related death | ||
| 520 | |a METHODS: This population-based study involved all 449,440 adult residents of the Reggio Emilia province, Italy. DM2 patients were divided in groups by COVID testing, presence of CAVDs and COVID death. Several mediation analyses were performed | ||
| 520 | |a RESULTS: Patients with DM2 had an increased likelihood of being tested (Odds ratio, OR 1.27 95 %CI 1.23-1.30), testing positive (OR 1.21 95 %CI 1.16-1.26) and dying from COVID-19 (OR 1.75 95 %CI 1.54-2.00). COVID-19-related death was almost three times higher among obese vs non-obese patients with DM2 (OR 4.3 vs 1.6, respectively). For COVID-19 death, CAVDs mediated a) just 5.1 % of the total effect of DM2, b) 40 % of the effect of DM2 duration, and c) did not mediate the effect of glycemic control | ||
| 520 | |a CONCLUSIONS: For COVID-19-related deaths in DM2 patients, the effect is mostly direct, obesity amplifies it, DM2 control and duration are important predictors, while CAVDs only slightly mediates it | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Mediation | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a SARS-CoV-2 | |
| 700 | 1 | |a Ottone, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Vicentini, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Venturelli, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Pezzarossi, Annamaria |e verfasserin |4 aut | |
| 700 | 1 | |a Manicardi, Valeria |e verfasserin |4 aut | |
| 700 | 1 | |a Greci, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgi Rossi, Paolo |e verfasserin |4 aut | |
| 700 | 0 | |a Reggio Emilia Covid-19 Working Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes research and clinical practice |d 1993 |g 191(2022) vom: 10. Sept., Seite 110051 |w (DE-627)NLM01260335X |x 1872-8227 |7 nnns |
| 773 | 1 | 8 | |g volume:191 |g year:2022 |g day:10 |g month:09 |g pages:110051 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.diabres.2022.110051 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 191 |j 2022 |b 10 |c 09 |h 110051 | ||